Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials

References

• Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994 Mar 1;83:1251–1257.
   PubMed Web of Science ®Google Scholar
• Van Ommen CH, Heijboer H, Büller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139:676–681.
   PubMed Web of Science ®Google Scholar
• Raffini L, Huang Y-S, Witmer C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009 Oct;124:1001–1008.
   PubMed Web of Science ®Google Scholar
• Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S–801S.
   PubMed Web of Science ®Google Scholar
• Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008 Sep 23;118:1373–1382.
   PubMed Web of Science ®Google Scholar
• Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res. 2003 Jan 25;109:85–92.
   PubMed Web of Science ®Google Scholar
• Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763–766.
   PubMed Web of Science ®Google Scholar
• Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr. 1998;133:770–776.
   PubMed Web of Science ®Google Scholar
• van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost. 2003 Dec;1:2516–2522.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423–428.
   PubMed Web of Science ®Google Scholar
• Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35:78–83.
   PubMed Web of Science ®Google Scholar
• Kuhle S, Eulmesekian P, Kavanagh B, et al. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica. 2007;92:244–247.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Bidlingmaier C, Krumpel A, et al. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008;153:1120–1127.
   PubMed Web of Science ®Google Scholar
• Goldenberg NA, Abshire T, Blatchford PJ, et al. Multicenter randomized controlled trial on duration of therapy for thrombosis in children and young adults (the Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost. 2015;13:1597–1605.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S–94S.
   PubMed Web of Science ®Google Scholar
• Holmgren K, Andersson G, Fagrell B, et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand. 1985;218:279–284.
   PubMedGoogle Scholar
• Schulman S, Lockner D, Juhlin Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. J Intern Med. 1985 Jan 12;217:547–552.
   Google Scholar
• O’Sullivan EF. Duration of anticoagulant therapy in venous thrombo-embolism. Med J Aust. 1972 Nov 11;2:1104–1107.
   PubMed Web of Science ®Google Scholar
• Society RCOTBT. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. The Lancet. 1992;30:873–876.
   Web of Science ®Google Scholar
• Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995 Jun 22;332:1661–1665.
   PubMed Web of Science ®Google Scholar
• Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001 May 22;103:2453–2460.
   PubMed Web of Science ®Google Scholar
• Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. 2007 Mar 31;334:674.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001 Jul 19;345:165–169.
   PubMed Web of Science ®Google Scholar
• Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006 Oct 26;355:1780–1789.
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 May 24;366:1959–1967.
   PubMed Web of Science ®Google Scholar
• Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734–742.
   PubMed Web of Science ®Google Scholar
• Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999 Mar 25;340:901–907.
   PubMed Web of Science ®Google Scholar
• Cosmi B, Legnani C, Tosetto A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010 Jan 21;115:481–488.
   PubMed Web of Science ®Google Scholar
• Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012 Nov 22;367:1979–1987.
   PubMed Web of Science ®Google Scholar
• Marik PE, Cavallazzi R. Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0143252.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361:2342–2352.
   PubMed Web of Science ®Google Scholar
• EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363:2499–2510.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Büller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369:799–808.
   PubMed Web of Science ®Google Scholar
• Kittelson JM, Spyropoulos AC, Halperin JL, et al. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost. 2013;11:1443–1448.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Büller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368:699–708.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 1995 Oct;108(4 Suppl):506S–522S.
   PubMed Web of Science ®Google Scholar
• Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165–172.
   PubMed Web of Science ®Google Scholar
• Newall F, Johnston L, Ignjatovic V, et al. Unfractionated heparin therapy in infants and children. Pediatrics. 2009 Mar 2;123:e510–8.
   PubMed Web of Science ®Google Scholar
• McDonald MM, Jacobson LJ, Hay WW, et al. Heparin clearance in the newborn. Pediatr Res. 1981;15:1015–1018.
   PubMedGoogle Scholar
• Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313–318.
   PubMed Web of Science ®Google Scholar
• Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999 Nov 1;94:3007–3014.
   PubMed Web of Science ®Google Scholar
• Goldenberg NA, Takemoto CM, Yee DL, et al. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood Am Soc Hematol. 2015 Dec 10;126:2541–2547.
   Google Scholar
• Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med. 2004 Sep 9;351:1081–1088.
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Tamma P, Kickler TS, et al. D-dimer for the diagnosis of venous thromboembolism in children. Am J Hematol. 2009;84:62–63.
   PubMed Web of Science ®Google Scholar
• Avila ML, Brandao LR, Williams S, et al. Development of CAPTSure(TM) - a new index for the assessment of pediatric postthrombotic syndrome. J Thromb Haemost. 2016;14:2376–2378.
   PubMed Web of Science ®Google Scholar